Overview of JAK Inhibitors
JAK inhibitors (jakinibs) are small molecule drugs that competitively inhibit the ATP-binding site of JAK kinase domains, blocking cytokine-mediated JAK-STAT signaling. Unlike biologic therapies (which target individual cytokines or receptors), jakinibs simultaneously block signaling from multiple cytokines that share JAK-dependent pathways.
This broad spectrum of action explains their efficacy across diverse inflammatory conditions but also contributes to their safety concerns (simultaneous suppression of multiple protective cytokine signals including EPO, thrombopoietin, and interferon pathways).
All FDA-approved jakinibs are oral small molecules with rapid onset (days to weeks), reversible kinetics, and half-lives of 12–17 hours (allowing once or twice-daily dosing). Their effects are rapidly reversible upon discontinuation — in contrast to some biologics with long half-lives.
FDA Approval: 2012 (RA) — first JAK inhibitor approved
Selectivity: JAK1/JAK3 (pan-JAK at higher doses, moderate JAK2 activity)
JAK Selectivity: JAK3 ≈ JAK1 >> JAK2 > TYK2
Inhibits γ-chain cytokines (IL-2, IL-4, IL-7, IL-15, IL-21) and IFN-gamma signaling
Approved Indications (US)
Rheumatoid Arthritis (RA)
Psoriatic Arthritis (PsA)
Ulcerative Colitis (UC)
Juvenile Idiopathic Arthritis (JIA)
Ankylosing Spondylitis (AS)
Dosing
- RA, PsA, AS, JIA: 5 mg twice daily or 11 mg XR once daily
- UC: 10 mg twice daily for 8 weeks induction, then 5 mg twice daily maintenance
- Renal/hepatic impairment: dose reduction required
Efficacy Highlights
In RA (ORAL-Standard trial): ACR20 response 59.8% vs 26.7% placebo at 6 months (MTX background). Non-inferior to adalimumab in head-to-head comparison (ORAL Strategy trial).
In UC (OCTAVE trials): clinical remission rate 18.5% vs 8.2% placebo at 8 weeks (induction).
Key Adverse Effects: Upper respiratory tract infection, nasopharyngitis, herpes zoster reactivation (dose-dependent, ~2–3× higher than TNF inhibitors), dyslipidemia (LDL/HDL elevation), anemia, neutropenia. See FDA Black Box Warnings section below.
FDA Approval: 2018 (RA), 2022 (Alopecia Areata — landmark: first systemic treatment for severe AA)
Selectivity: JAK1/JAK2 (also inhibits TYK2 and AAK1/GAK — endocytic recycling kinases)
JAK Selectivity: JAK1 ≈ JAK2 > TYK2 > JAK3
Inhibits gp130 cytokines (IL-6), IFN pathways, and hematopoietic cytokines (EPO, TPO)
Approved Indications (US)
Rheumatoid Arthritis (RA) — 2 mg/day
Alopecia Areata — 2 mg or 4 mg/day
COVID-19 (hospitalized, requiring supplemental O2) — 4 mg/day
Dosing
- RA: 2 mg once daily (US label); 4 mg in Europe and in alopecia areata
- Alopecia Areata: 2 mg or 4 mg once daily
- Renal dose adjustment required for eGFR <60 mL/min
Alopecia Areata Indication
Baricitinib's approval for alopecia areata (BRAVE-AA1 and BRAVE-AA2 trials) was a watershed moment — the first FDA-approved systemic drug for severe AA. In BRAVE-AA2: 35.9% of baricitinib 4 mg patients achieved SALT ≤20 (≥80% scalp hair coverage) vs 6.6% placebo. The mechanism involves blocking JAK1/JAK2-dependent IFN-gamma and IL-15 signaling that drives the collapse of hair follicle immune privilege.
Key Adverse Effects: Upper respiratory infections, nausea, increased lipids, anemia (JAK2 inhibition reduces EPO signaling), thrombocytopenia. AAK1 inhibition (unique to baricitinib) may impair clathrin-mediated endocytosis — possible role in reducing viral entry (studied in COVID-19).
FDA Approval: 2019 (RA) — AbbVie's engineered selective JAK1 inhibitor
Selectivity: JAK1 >>> JAK2, JAK3, TYK2 (approximately 60-75× selectivity for JAK1 over JAK2)
JAK Selectivity: JAK1 selective (>60× over JAK2)
Designed to spare JAK2-dependent EPO/TPO signaling — potentially better hematologic safety
Approved Indications (US)
Rheumatoid Arthritis (RA)
Psoriatic Arthritis (PsA)
Ankylosing Spondylitis (AS)
nr-axSpA
Atopic Dermatitis (AD)
Ulcerative Colitis (UC)
Crohn's Disease (CD)
Dosing by Indication
- RA: 15 mg once daily
- PsA, AS, nr-axSpA: 15 mg once daily
- Atopic Dermatitis (AD): 15 mg (moderate-to-severe) or 30 mg once daily
- UC, CD: 45 mg once daily for 8 weeks (induction), then 15 or 30 mg once daily (maintenance)
Atopic Dermatitis Efficacy
Upadacitinib represents a major advance in atopic dermatitis. In MEASURE UP-1 trial (15 mg): 39.6% IGA 0/1 response vs 6.3% placebo. In SELECT-COMPARE (RA head-to-head): superior DAS28-CRP remission vs adalimumab at 12 weeks. It has the broadest approved indication set of any JAK inhibitor.
Key Adverse Effects: Acne/folliculitis (particularly at 30 mg dose in AD — ~11%), nausea, anemia, neutropenia, herpes zoster, elevated CPK, dyslipidemia. Similar class-effect safety profile to other JAK inhibitors.
FDA Approval: 2011 (Myelofibrosis) — first JAK inhibitor approved for any indication
Selectivity: JAK1/JAK2 (equipotent)
JAK Selectivity: JAK1 ≈ JAK2
Strong JAK2 inhibition — directly reduces JAK2 V617F-driven clonal hematopoiesis
Approved Indications (US)
Myelofibrosis (MF) — intermediate/high-risk
Polycythemia Vera (PV) — hydroxyurea refractory/intolerant
Steroid-refractory Acute GvHD
Chronic GvHD
Atopic Dermatitis (topical Opzelura)
Vitiligo (topical Opzelura)
Myelofibrosis Efficacy
The pivotal COMFORT-I and COMFORT-II trials demonstrated ruxolitinib's benefit in myelofibrosis: spleen volume reduction ≥35% in 41.9% vs 0.7% (best available therapy); symptom score improvement ≥50% in 45.9% vs 5.3% at week 24. Overall survival benefit was demonstrated in long-term follow-up. The drug targets the constitutively active JAK2 V617F kinase that drives the malignant clone in most MF/PV patients.
Dosing
- MF: Starting dose 15 or 20 mg twice daily (based on platelet count); individualized dose titration
- PV: 10 mg twice daily initially; titrate to hematocrit control
- Acute GvHD: 5 mg twice daily
- Topical Opzelura (1.5% cream): Apply to affected areas twice daily
Key Adverse Effects: Anemia (often requires transfusion in MF), thrombocytopenia, neutropenia, herpes zoster and other opportunistic infections (including PCP — consider trimethoprim-sulfamethoxazole prophylaxis), abrupt discontinuation syndrome (rapidly increasing spleen size, cytokine storm — taper dose). Non-melanoma skin cancers (long-term MF treatment).
FDA Black Box Warnings (Class Effect — All Oral JAK Inhibitors)
FDA Required Class Warnings (September 2021 / Updated 2022)
Following analysis of the post-marketing safety trial ORAL Surveillance (tofacitinib), the FDA issued strengthened warnings applicable to all oral JAK inhibitors:
- Serious Infections: Patients are at increased risk for serious bacterial, fungal, viral, and opportunistic infections. Herpes zoster reactivation occurs at higher rates than with TNF inhibitors. Active infections should be treated before initiating therapy. Test for tuberculosis prior to treatment.
- Mortality: Higher all-cause mortality observed with tofacitinib 10 mg twice daily vs TNF inhibitors in ORAL Surveillance (primarily cardiovascular death and infection). Risk appears higher in patients aged ≥65 years.
- Major Adverse Cardiovascular Events (MACE): Tofacitinib (10 mg BID) associated with increased risk of MACE (MI, stroke, CV death) vs TNF inhibitors, particularly in current or past smokers. The FDA advises consideration of cardiovascular risk before prescribing.
- Thrombosis: DVT, pulmonary embolism, and arterial thrombosis reported. Risk appears higher with higher doses. Avoid use in patients at high risk of thrombosis.
- Malignancy: Increased risk of lymphoma and solid tumors, particularly in patients with known malignancy. Lung cancer, breast cancer, and melanoma reported. Use with caution in current/past smokers.
Restricted Use: All oral JAK inhibitors for inflammatory conditions now have a restricted use note: use only in patients who have had inadequate response or intolerance to one or more TNF blockers, unless no alternatives exist.
Comparison of Approved JAK Inhibitors
| Drug | Selectivity | Route | Approved US Indications | Key Concern |
|---|
| Tofacitinib | JAK1/3 | Oral | RA, PsA, UC, AS, JIA | MACE, malignancy, thrombosis |
| Baricitinib | JAK1/2 | Oral | RA, alopecia areata, COVID-19 | Anemia (JAK2), thrombosis |
| Upadacitinib | JAK1 selective | Oral | RA, PsA, AS, AD, UC, CD, nr-axSpA | Acne, broadest indication set |
| Ruxolitinib | JAK1/2 | Oral / Topical | MF, PV, GvHD, AD, vitiligo | Anemia, thrombocytopenia, abrupt d/c |
| Deucravacitinib | TYK2 (allosteric) | Oral | Plaque psoriasis | Different safety profile — no JAK1/2/3 |
| Abrocitinib | JAK1 selective | Oral | Atopic Dermatitis | Thrombocytopenia (more than upadacitinib) |
Follow JAK Inhibitor Research
Subscribe for updates on new approvals, safety data, and clinical trial results.